Lifecore Biomedical (LFCR) to Release Quarterly Earnings on Thursday

Lifecore Biomedical (NASDAQ:LFCR) is anticipated to release its earnings data on Thursday, April 3rd. Analysts expect Lifecore Biomedical to post earnings of ($0.14) per share and revenue of $33.23 million for the quarter. Investors that are interested in participating in the company’s conference call can do so using this link.

Lifecore Biomedical (NASDAQ:LFCR) last issued its quarterly earnings results on Thursday, January 2nd. The company reported ($0.25) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.27) by $0.02. Lifecore Biomedical had a negative return on equity of 315.23% and a negative net margin of 12.52%. On average, analysts expect Lifecore Biomedical to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Lifecore Biomedical Price Performance

Shares of LFCR stock opened at $7.04 on Tuesday. Lifecore Biomedical has a 12 month low of $3.68 and a 12 month high of $7.99. The company has a market capitalization of $260.66 million, a P/E ratio of -12.57 and a beta of 0.96. The stock has a 50 day moving average of $6.15 and a two-hundred day moving average of $6.22. The company has a current ratio of 2.32, a quick ratio of 1.21 and a debt-to-equity ratio of 9.21.

Insiders Place Their Bets

In related news, CEO Paul Josephs acquired 17,000 shares of the company’s stock in a transaction on Wednesday, January 8th. The stock was purchased at an average cost of $5.74 per share, for a total transaction of $97,580.00. Following the completion of the purchase, the chief executive officer now directly owns 559,717 shares of the company’s stock, valued at $3,212,775.58. The trade was a 3.13 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 32.20% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Stephens reiterated an “equal weight” rating and set a $6.00 price target on shares of Lifecore Biomedical in a research note on Friday, January 3rd.

About Lifecore Biomedical

Lifecore Biomedical, Inc, together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures.